7.1  0.32 (4.72%)		01-08 15:53
Open: 6.57 High: 8.025 Volume: 11,101		Pre. Close: 6.78 Low: 6.57 Market Cap: 64(M)

Short term
Mid term
Targets	6-month :	9.55	1-year :	11.09
Resists	First :	8.18	Second :	9.5
Pivot price	7.37
Supports	First :	6.05	Second :	5.03
MAs	MA(5) :	7.3	MA(20) :	7.19
	MA(100) :	7.53	MA(250) :	0
MACD	MACD :	0	Signal :	0.1
%K %D	K(14,3) :	31.2	D(3) :	36.7
RSI	RSI(14): 48.1
52-week	High :	9.98	Low :	5.9

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ NSRX ] has closed above bottom band by 39.2%. Bollinger Bands are 0% narrower than normal.

If tomorrow:	Open lower	Open higher
High:	8.04 - 8.08	8.08 - 8.12
Low:	6.47 - 6.52	6.52 - 6.56
Close:	7.02 - 7.1	7.1 - 7.17

Nasus Pharma is a clinical-stage specialty pharmaceutical company focused primarily on the development of intranasal drugs to treat emergency medical conditions such as severe allergies, anaphylaxis, and opioid overdose. Their lead products include NS002, an intranasal powder epinephrine nasal spray for type 1 severe allergies and anaphylaxis, and NS001, an intranasal naloxone powder spray for opioid overdose. They use a powder-based intranasal technology that offers rapid drug absorption.

Mon, 29 Dec 2025
Nasus Pharma Reports Wider Interim Loss and Deepening Shareholders’ Deficit in June 2025 Results - TipRanks

Mon, 22 Dec 2025
Nasus Pharma Highlights Transformational 2025 as NS002 Intranasal Epinephrine Program Advances and IPO Completes - TipRanks

Mon, 22 Dec 2025
Nasus Pharma CEO Issues 2025 Letter to Shareholders - GlobeNewswire

Thu, 18 Dec 2025
NSRX: Citizens Initiates Coverage with Market Outperform Rating at $19 Price Target | NSRX Stock News - GuruFocus

Thu, 18 Dec 2025
Citizens Initiates Coverage of Nasus Pharma (NSRX) with Market Outperform Recommendation - Nasdaq

Tue, 18 Nov 2025
BitMine Immersion (NYSE: BMNR) prices stock at $70, 14% premium in direct offering - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.